Article info

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

Authors

  1. Correspondence to Professor Shigeto Kobayashi, Juntendo University Koshigaya Hospital, Saitama, Japan; shigeto{at}juntendo.ac.jp
View Full Text

Citation

Wei JC, Kim T, Kishimoto M 4827-006 study group, et al
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

Publication history

  • Received October 28, 2020
  • Revised March 12, 2021
  • Accepted March 13, 2021
  • First published April 7, 2021.

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.